The short version of Peptide stability fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-10 and is reviewed periodically as new material appears.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
== External links == 'When Heroin Was Legal' BBC Drug-poisoning Deaths Involving Heroin: United States, 2000–2013 US Department of Health and Human Services Heroin Trafficking in the United States Archived 18 July 2020 at the Wayback Machine (2019) US Congressional Research Service
RNAP initiates transcription of the trp promoter. RNAP pauses at about nucleotide 90 at a secondary structure (?the first one shown above?). Ribosomes engage this nascent mRNA and initiate translation of the leader peptide. RNAP is then "released" from its pause and continues transcription. When RNAP reaches the region of the potential terminator, whether it continues or not is dependent on the position of the ribosome "trailing behind". If the ribosome stalls at the tandem Trp codons, waiting for the appropriate tRNA, region 1 is sequestered within the ribosome and thus cannot base pair with region 2. This means that region 2 and 3 become based paired before region 4 can be transcribed. This forces region 4 when it is made to be single stranded, preventing the formation of the region 3/4 terminator structure. Transcription will then continue. If the ribosome translates the leader peptide with no hesitation, it then covers a portion of region 2 preventing it from base pairing with region 3. Then when region 4 is transcribed, it forms a stem and loop with region 3 and transcription is terminated, generating a ca. 140 base transcript. This mechanism of control measures the amount of available, charged Trp-tRNA. The location of ribosomes determines which alternate secondary structures form.
=== Legal status === United States: During clinical trials a small number of users (~4%) reported euphoria after use, which led to its control in the US. The Drug Enforcement Administration (DEA) classified pregabalin as a depressant and placed pregabalin, including its salts, and all products containing pregabalin into Schedule V of the Controlled Substances Act. Norway: Pregabalin is in prescription Schedule B, alongside benzodiazepines. United Kingdom: On January 14, 2016, the Advisory Council on the Misuse of Drugs (ACMD) recommended that pregabalin, along with gabapentin, be controlled under the Misuse of Drugs Act 1971. In October 2018, it was announced that pregabalin would be reclassified as a Class C controlled substance, effective April 2019. As a Class C drug, pregabalin now requires a prescription in the UK, and the prescription must clearly specify the dose. Australia: Pregabalin has been classified as Schedule 4 (prescription only) since its registration in Australia in 2005. Despite this classification, concerns about misuse and deaths led the Therapeutic Goods Administration (TGA) to add boxed warnings regarding abuse and dependence to pregabalin's prescribing information in 2021. Data from the National Coronial Information System showed pregabalin-related deaths rose from 16 in 2013 to 121 in 2016, and a 2019 study in the Medical Journal of Australia found over a tenfold increase in pregabalin-related ambulance attendances in Victoria between 2012 and 2017. Pregabalin is subject to real-time prescription monitoring in all states and territories.
==== Remdesivir/baricitinib ==== In May 2020, the National Institute of Allergy and Infectious Diseases (NIAID) started the Adaptive COVID‑19 Treatment Trial 2 (ACTT-2) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus baricitinib for treating hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation. In November 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The data supporting the EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The EUA was issued to Eli Lilly and Company.
Sources: en.wikipedia.org
David G. Armstrong (born February 18, 1969) is an American podiatric surgeon and academic known for his work in diabetic foot care, wound healing, and limb preservation. He is a Distinguished Professor of Surgery and Neurological Surgery at the University of Southern California (USC), where he directs the university's Center to Stream Healthcare in Place (C2SHiP), a National Science Foundation–funded initiative focused on advancing home-based health technologies and care models. Armstrong is the founding president of the American Limb Preservation Society (ALPS) and co-founder and co-chair of the International Diabetic Foot Conference (DFCon), the largest annual international symposium on the diabetic foot in the world. He also co-founded the Southwestern Academic Limb Salvage Alliance (SALSA) and has contributed to the development of interdisciplinary strategies for managing chronic limb-threatening ischemia and preventing diabetes-related amputations.
=== Engine === Chainsaw engines are traditionally either a two-stroke single-cylinder gasoline (petrol) internal combustion engine (usually with a cylinder volume of 30 to 120 cc) or an electric motor driven by a battery or electric power cord. In a petrol chainsaw, fuel is generally supplied to the engine by a carburetor at the intake. Two-stroke engines have been preferred for chainsaws due to their higher power-to-weight ratio and simplicity. Hydraulic power may be used for chainsaws for underwater use. To allow use in any orientation, modern gasoline chainsaws use a diaphragm carburetor, which draws fuel from the tank using the alternating pressure differential within the crankcase. Early engines used carburetors with gravity fed float chambers, which caused the engine to stall when tilted. The carburetor may need to be adjusted to maintain an appropriate idle speed and air-fuel ratio, such as when moving to a higher/lower altitude or as the air filter clogs. Carburetors are adjusted either by the operator or, in some saws, automatically by an electronic control unit. To prevent vibration induced injury and reduce user fatigue, saws generally have an anti-vibration system to physically decouple the handles from the engine and bar. This is achieved by constructing the saw in two pieces, connected by springs or rubber in the same way an automobile suspension isolates the chassis from the wheels and road. In cold weather, carburetor icing can occur, so many saws have a vent between the cylinders and carburetor which may be opened to allow hot air to pass.
=== Concentration of executive power === A month after the beginning of the presidency, the government had been sued 200 times for "executive overreach", which the administration lost for the most part. On Twitter, Trump justified his policies by quoting Napoleon: "He who saves his Country does not violate any Law". In reaction, the American left accused him of acting as a dictator. The right-wing and left-wing media both claim that their policies allowed a hitherto concentration of executive power in US history. Experts and newspapers feared a constitutional crisis because of frequent checks and balances breaches. The Trump administration often questioned the legitimacy of judges blocking his executive orders. According to The New Yorker, Trump's new governance based itself on unconditional loyalty towards himself. Trump allegedly implemented a climate where any criticism even among the Republicans is sanctioned. Figures like Jack Posobiec and Laura Loomer acted as ideological safeguards by listing potential dissidents among the party. The administrations openly wanted to concentrate political powers within Trump's hands. They justify it with the unitary executive theory, alleging that by having been elected and with the approval of the Constitution, Trump is warranted in having unchecked and absolute power on the judicial branch, and on politics in general.
Channa amari Dey et al., 2019 — likely a synonym of C. brunnea Channa amphibeus (McClelland, 1845) (Borna snakehead) Channa andrao Britz, 2013 Channa ara (Deraniyagala, 1945) Channa argus (Cantor, 1842) (northern snakehead) Channa aristonei Praveenraj, Thackeray, Singh, Uma, Moulitharan & Mukhim, 2020 Channa asiatica (Linnaeus, 1758) (small snakehead) Channa aurantimaculata Musikasinthorn, 2000 (orange-spotted snakehead) Channa aurantipectoralis Lalhlimpuia, Lalronunga & Lalramliana, 2016 Channa auroflammea Adamson, Britz and S. Lieng, 2019 Channa aurolineata (F. Day, 1870) Channa bankanensis (Bleeker, 1853) Channa baramensis (Steindachner, 1901) Channa barca (F. Hamilton, 1822) (barca snakehead) Channa bipuli Praveenraj, Uma, Moulitharan & Bleher, 2018 Channa bleheri Vierke, 1991 (rainbow snakehead) Channa brahmacharyi Chakraborty, Yardi & Mukherjee, 2020 Channa brunnea Praveenraj, Uma, Moulitharan & Kannan, 2019 Channa burmanica B. L. Chaudhuri, 1919 Channa coccinea Britz, H. H. Tan & Rüber, 2024 Channa cyanospilos (Bleeker, 1853) Channa diplogramma (F. Day, 1865) (Malabar snakehead) Channa gachua (F. Hamilton, 1822) (dwarf snakehead) Channa harcourtbutleri (Annandale, 1918) (Burmese snakehead) Channa hoaluensis Nguyen, 2011 Channa kelaartii (Günther, 1861) Channa limbata (Cuvier, 1831) Channa lipor Praveenraj, Uma, Moulitharan & Singh, 2019 Channa longistomata (Nguyen & Nguyen, 2012) Channa lucius (G. Cuvier, 1831) (forest snakehead) Channa maculata (Lacépède, 1801) (blotched snakehead) Channa marulioides (Bleeker, 1851) (emperor snakehead) Channa marulius (F.
The two substrates of this enzyme are (S)-3-(imidazol-5-yl)lactic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are imidazole-4-pyruvic acid, reduced NADH, and a proton. The enzyme can use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-3-(imidazol-5-yl)lactate:NAD(P)+ oxidoreductase. This enzyme is also called imidazol-5-yl lactate dehydrogenase.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.